Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma with Carfilzomib Lenalidomide Dexamethasone (CRD)

What is the purpose of this trial?

The primary objective of this study is to compare the detection rate of residual/refractory disease based on standard bone marrow biopsy versus guided myeloma lesion biopsy after induction therapy with carfilzomib, lenalidomide and dexamethasone regimen.

Yale Cancer Center

Start Date: 06/04/2018

End Date: 07/05/2020

Last Updated: 06/22/2018

Study HIC#: 2000021421

Get Involved

For more information about this study, contact:
Laura Leary

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email or call 1-877-978-8348.

Trial Image